ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today reported that total revenue for the fourth quarter of 2007 increased 6% to $6.70 million from total revenue of $6.34 million for the fourth quarter of 2006. In the fourth quarter of 2007, revenue in the U.S. was $4.79 million, an increase of 5% compared to revenue of $4.58 million in the fourth quarter of 2006. Revenue in Europe, Mid-East and Africa (EMEA) rose 18% to $1.78 million for the fourth quarter of 2007 from $1.51 million for the same period in 2006. In markets outside of the United States and EMEA, revenue in Rest of World (ROW) markets declined by 48% to $0.13 million for the fourth quarter of 2007 from $0.25 million for the same period in 2006.
